日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

The designer cytokine IC7Fc attenuates atherosclerosis development by targeting hyperlipidemia in mice

人工设计的细胞因子IC7Fc通过靶向小鼠高脂血症来减缓动脉粥样硬化的发展。

Wietse In Het Panhuis ,Ellen Thiemann ,Daisy M A H van Dijk ,Bibian Been ,Kelsey E Jarrett ,Amber Meurs ,Sander Kooijman ,Milaine V Hovingh ,Melanie Modder ,Bram W van Os ,Thijs J Sluiter ,Niek Blomberg ,Amanda C M Pronk ,Salwa Afkir ,Trea C M Streefland ,Reshma A Lalai ,Maria O Taveras ,Sen Zhang ,Timothy E Adams ,Lauren V Terry ,Sarah M Turpin-Nolan ,Margreet R de Vries ,Martin Giera ,Stefan Rose-John ,Noam Zelcer ,Jan Freark de Boer ,Thomas Q de Aguiar Vallim ,Mark A Febbraio ,Patrick C N Rensen ,Milena Schönke

Decorin, an exercise-induced secretory protein, is associated with improved prognosis in breast cancer patients but does not mediate anti-tumorigenic tissue crosstalk in mice

Decorin是一种运动诱导分泌蛋白,与乳腺癌患者预后改善相关,但它并不介导小鼠体内的抗肿瘤组织间相互作用。

Marit Hjorth,Casey L Egan,Guilherme D Telles,Martin Pal,David Gallego-Ortega,Oliver K Fuller,Emma D McLennan,Ryan D Gillis,Tae Gyu Oh,George E O Muscat,Surafel Tegegne,Michael S M Mah,Joanna Skhinas,Emma Estevez,Timothy E Adams,Matthew J McKay,Mark Molloy,Kevin I Watt,Hongwei Qian,Paul Gregorevic,Thomas R Cox,Pernille Hojman,Julie Midtgaard,Jesper F Christensen,Martin Friedrichsen,Renato V Iozzo,Erica K Sloan,Brian G Drew,Jørgen F P Wojtaszewski,Martin Whitham,Mark A Febbraio

CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy

CUB 结构域蛋白 1 (CDCP1) 是开发用于癌症检测和治疗的成像示踪剂和抗体-药物偶联物的合理靶点

Tashbib Khan, Nicholas J Lyons, Madeline Gough, Kayden K X Kwah, Tahleesa J Cuda, Cameron E Snell, Brian W Tse, Kamil A Sokolowski, Lesley A Pearce, Timothy E Adams, Stephen E Rose, Simon Puttick, Marina Pajic, Mark N Adams, Yaowu He, John D Hooper, Thomas Kryza

Molecular characterisation of ILRUN, a novel inhibitor of proinflammatory and antimicrobial cytokines

新型促炎和抗菌细胞因子抑制剂 ILRUN 的分子表征

Rebecca L Ambrose, Aaron M Brice, Alessandro T Caputo, Marina R Alexander, Leon Tribolet, Yu Chih Liu, Timothy E Adams, Andrew G D Bean, Cameron R Stewart

Treatment of type 2 diabetes with the designer cytokine IC7Fc

使用设计细胞因子 IC7Fc 治疗 2 型糖尿病

Maria Findeisen #, Tamara L Allen #, Darren C Henstridge, Helene Kammoun, Amanda E Brandon, Laurie L Baggio, Kevin I Watt, Martin Pal, Lena Cron, Emma Estevez, Christine Yang, Greg M Kowalski, Liam O'Reilly, Casey Egan, Emily Sun, Le May Thai, Guy Krippner, Timothy E Adams, Robert S Lee, Joachim Grö

Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma

大多数临床抗 EGFR 抗体不能中和胶质瘤中的 wtEGFR 和 EGFRvIII 激活

Sameer A Greenall, Mathew McKenzie, Ekatarina Seminova, Olan Dolezal, Lesley Pearce, John Bentley, Mani Kuchibhotla, Shengnan C Chen, Kerrie L McDonald, Harley I Kornblum, Raelene Endersby, Timothy E Adams, Terrance G Johns

Specific Sialoforms Required for the Immune Suppressive Activity of Human Soluble CD52

人可溶性 CD52 免疫抑制活性所需的特定唾液酸形式

Abdulrahman M Shathili, Esther Bandala-Sanchez, Alan John, Ethan D Goddard-Borger, Morten Thaysen-Andersen, Arun V Everest-Dass, Timothy E Adams, Leonard C Harrison, Nicolle H Packer

CD52 inhibits Toll-like receptor activation of NF-κB and triggers apoptosis to suppress inflammation

CD52 抑制 NF-κB 的 Toll 样受体激活并引发细胞凋亡以抑制炎症

Maryam Rashidi, Esther Bandala-Sanchez, Kate E Lawlor, Yuxia Zhang, Alana M Neale, Swarna L Vijayaraj, Robert O'Donoghue, John M Wentworth, Timothy E Adams, James E Vince, Leonard C Harrison

Differential Sensitivity of Human Hepatocellular Carcinoma Xenografts to an IGF-II Neutralizing Antibody May Involve Activated STAT3

人类肝细胞癌异种移植对 IGF-II 中和抗体的差异敏感性可能涉及激活的 STAT3

Sameer A Greenall, Jacqueline Donoghue, Terrance G Johns, Timothy E Adams

C6orf106 is a novel inhibitor of the interferon-regulatory factor 3-dependent innate antiviral response

C6orf106 是一种新型干扰素调节因子 3 依赖性先天抗病毒反应抑制剂

Rebecca L Ambrose, Yu Chih Liu, Timothy E Adams, Andrew G D Bean, Cameron R Stewart